INSIGHT. What trends will dominate in life science and digital health in 2024? Here are some insights from us at Sciety. 1. Synthetic biology and artificial cells Synthetic biology is a field of research where it’s chemically feasible to construct entirely new organisms and modify existing ones, giving them new
PRESS RELEASE. Sciety’s portfolio company Capitainer, a Swedish medtech company that develops intelligent solutions for self-sampling of blood and plasma, has received a SEK 30 million investment from We Venture Capital, the venture capital arm of the globally renowned Werfen Group. This strategic investment marks a milestone in Capitainer’s journey
CASE STUDY. In this case study, we’re taking a look at how Capitainer strengthened their market position through a strategic partnership with Sciety. It all started when Capitainer, a medtech company specialising in at-home blood and urine sampling technologies, needed to raise external capital to make their vision a reality.
PRESS RELEASE. Sciety and Sciety Venture Partners have recently completed an investment in the Swedish pharmaceutical company PharmNovo, developing a new type of drug for nerve pain. The funds were raised through convertible debentures, providing PharmNovo with SEK 23.1 million for the company’s continued development. Karolinska Development and Almi Invest
NEWS. Sciety supports innovative companies in life science and digital health. We help them grow and become successful, so that scientific breakthroughs in medicine and technology can become available to people all over the world. During the fall we continued our journey towards this goal, together with our portfolio companies.
NEWS. On November 9, 2023, Sciety invited its investor network to an exclusive event on the theme of future scenarios and opportunities within life science. The evening featured a panel discussion on data-driven precision medicine with Tommi Unkuri, Partner and Co-founder of Summa Equity; Mattias Häggblom, Sector Head for Healthcare,